Español
drug delivery
OLIGOFASTX aims to combine resources and efforts to create a platform that facilitates and contributes to the generation in Spain of a biopharmaceutical industrial fabric specialised in the development of oligonucleotide-based therapies with RNA as a common thread.
The project seeks long-term collaboration based on complementarity between companies and specialised research centres, covering the entire development cycle of these drugs.
•
Mission
OLIGOFASTX has the ultimate goal of pooling resources and efforts to create a comprehensive platform to facilitate and contribute to the accelerated development of RNA oligonucleotide-based therapies (ASOs, siRNAs and aptamers) in Spain.
The seven constituent entities are specialised in the different activities necessary to complete the oligonucleotide-based drug development cycle, creating the industrial fabric necessary for the emergence of new RNA-based therapies.
Objectives
- The development of a comprehensive platform for new therapies based on three oligonucleotide-based technologies, Antagomirss, siRNAs and Aptamers, to boost and facilitate the arrival on the market of new therapies for the treatment of rare diseases with no medical response.
- The constitution of an integrated system of activities and processes through collaboration between entities that will enable the design, synthesis, release and development of RNA-based drugs. This system will make it possible to address the treatment of any disease – both rare and high-incidence – although the framework of the CDTI-funded project is limited to developments for rare diseases.
OLIGOFASTX is a multidisciplinary consortium led by Sylentis (PharmaMar Group) with the participation of six other Spanish companies.
Design, modeling and AI
Nanotechnology and drug delivery
Therapy
Development
Production
and escaling
